Compare · BWAY vs DXCM
BWAY vs DXCM
Side-by-side comparison of BrainsWay Ltd. (BWAY) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BWAY and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.08B, about 50.0x BWAY ($562.1M).
- Over the past year, BWAY is up 175.0% and DXCM is down 16.2% - BWAY leads by 191.1 points.
- DXCM has been more active in the news (30 items in the past 4 weeks vs 10 for BWAY).
- DXCM has more recent analyst coverage (25 ratings vs 5 for BWAY).
- Company
- BrainsWay Ltd.
- DexCom Inc.
- Price
- $14.05-3.80%
- $72.74-0.92%
- Market cap
- $562.1M
- $28.08B
- 1M return
- -14.41%
- +21.17%
- 1Y return
- +174.95%
- -16.20%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2005
- News (4w)
- 10
- 30
- Recent ratings
- 5
- 25
BrainsWay Ltd.
Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic stimulation technology for the treatment of major depressive disorders, obsessive-compulsive disorders, bipolar disorders, post traumatic stress disorders, schizophrenia, smoking cessation, Alzheimer's disease, Asperger syndromes, alcohol addictions, attention deficit hyperactivity disorders, Parkinson's disease, and chronic neuropathic pains to transmit electric current flows at varying rates and creating an electromagnetic field that serves to depolarize cortical neurons and activate neural networks in various areas of the brain. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest BWAY
- Chief Scientist Roth Yiftach sold 7,000 units of Ordinary Shares, decreasing direct ownership by 0.65% to 1,072,305 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by BrainsWay Ltd.
- Director Mitrany Rayten Michal Ety sold 17,980 units of Ordinary Shares, decreasing direct ownership by 59% to 12,500 units (SEC Form 4)
- Director Mitrany Rayten Michal Ety converted options into 27,500 units of Ordinary Shares and covered exercise/tax liability with 9,520 units of Ordinary Shares, increasing direct ownership by 144% to 30,480 units (SEC Form 4)
- SEC Form 6-K filed by BrainsWay Ltd.
- BrainsWay Announces Minority-Stake Investment in Hopemark Health
- SEC Form 6-K filed by BrainsWay Ltd.
- Amendment: SEC Form SCHEDULE 13G/A filed by BrainsWay Ltd.
- SEC Form 6-K filed by BrainsWay Ltd.
- BrainsWay Reports First Quarter 2026 Financial Results and Operational Highlights
Latest DXCM
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
- Director Driscoll Rimma was granted 5,605 shares, increasing direct ownership by 48% to 17,319 units (SEC Form 4)
- Director Ashley Euan A. was granted 5,565 shares, increasing direct ownership by 78% to 12,731 units (SEC Form 4)
- Director Collins Richard Alexander was granted 5,605 shares (SEC Form 4)